Influenza Clinical Trial
— TaxErOfficial title:
A Pilot Study of Dietary Taxifolin/Dihydroquercetin and Ergothioneine and Immune Biomarkers in Healthy Volunteers
Verified date | May 2024 |
Source | University of Southampton |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
The complexities of the immune system make measuring the impact of dietary interventions upon its function challenging. The immune system is highly responsive to environmental influences, including the diet. An individual's diet provides the energy required to mount a strong and protective immune response, the building blocks required for synthesis of immune mediators such as antibodies and cytokines, and can also indirectly affect immune function via changes in the gut microbiome. Immune function varies across the lifecourse, with a well understood decline in immune function with age, resulting in impaired vaccination responses and an increased risk of infections and of severe complications and mortality arising from common communicable diseases such as influenza. This impaired immunity with ageing is known as immunosenescence and this affects both innate and acquired arms of the immune system.
Status | Active, not recruiting |
Enrollment | 90 |
Est. completion date | August 2024 |
Est. primary completion date | September 29, 2022 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 50 Years to 65 Years |
Eligibility | Inclusion Criteria: - age 50-65yr - BMI 18.5-30kg/m2 - Willing to avoid consumption of foods rich in Taxifolin/DHQ and Ergothioneine during the study period - Willing to avoid taking any other food supplements or high doses of vitamins during the study period - Able to provide written informed consent. Exclusion Criteria: - Use of prescription medication which may influence immune function, such as anti-inflammatory or immunosuppressant medication - Diabetes requiring any medication - Liver cirrhosis - A history of drug or alcohol misuse - Asplenia or other acquired or congenital immunodeficiencies - Any autoimmune disease including connective tissue diseases - Malignancy - Laboratory confirmed SARS-CoV-2 infection within last 3 months - self-reported symptoms of acute or recent infection (including use of antibiotics within the last 3 months) |
Country | Name | City | State |
---|---|---|---|
United Kingdom | NIHR Southampton Biomedical Research Centre | Southampton | Hampshire |
Lead Sponsor | Collaborator |
---|---|
University of Southampton | Blue California |
United Kingdom,
Albers R, Bourdet-Sicard R, Braun D, Calder PC, Herz U, Lambert C, Lenoir-Wijnkoop I, Meheust A, Ouwehand A, Phothirath P, Sako T, Salminen S, Siemensma A, van Loveren H, Sack U. Monitoring immune modulation by nutrition in the general population: identifying and substantiating effects on human health. Br J Nutr. 2013 Aug;110 Suppl 2:S1-30. doi: 10.1017/S0007114513001505. — View Citation
Childs, C. E., & Calder, P. C. (2017). Modifying the gut microbiome through diet: effects on the immune system of elderly subjects. In T. Fulop, C. Franceschi, K. Hirokawa, & G. Pawelec (Eds.), Handbook of Immunosenescence Cham: Springer International Publishing AG. DOI: 10.1007/978-3-319-64597-1_160-1
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter J, Gelbmann W, Van Loveren H. Scientific Opinion on taxifolin-rich extract from Dahurian Larch (Larix gmelinii). EFSA J. 2017 Feb 14;15(2):e04682. doi: 10.2903/j.efsa.2017.4682. eCollection 2017 Feb. — View Citation
EFSA Panel on Dietetic Products, Nutrition and Allergies (NDA); Turck D, Bresson JL, Burlingame B, Dean T, Fairweather-Tait S, Heinonen M, Hirsch-Ernst KI, Mangelsdorf I, McArdle HJ, Naska A, Neuhauser-Berthold M, Nowicka G, Pentieva K, Sanz Y, Siani A, Sjodin A, Stern M, Tome D, Vinceti M, Willatts P, Engel KH, Marchelli R, Poting A, Poulsen M, Schlatter JR, Ackerl R, van Loveren H. Statement on the safety of synthetic l-ergothioneine as a novel food - supplementary dietary exposure and safety assessment for infants and young children, pregnant and breastfeeding women. EFSA J. 2017 Nov 13;15(11):e05060. doi: 10.2903/j.efsa.2017.5060. eCollection 2017 Nov. — View Citation
Ey J, Schomig E, Taubert D. Dietary sources and antioxidant effects of ergothioneine. J Agric Food Chem. 2007 Aug 8;55(16):6466-74. doi: 10.1021/jf071328f. Epub 2007 Jul 6. — View Citation
Kang M, Ragan BG, Park JH. Issues in outcomes research: an overview of randomization techniques for clinical trials. J Athl Train. 2008 Apr-Jun;43(2):215-21. doi: 10.4085/1062-6050-43.2.215. — View Citation
Przemska-Kosicka A, Childs CE, Enani S, Maidens C, Dong H, Dayel IB, Tuohy K, Todd S, Gosney MA, Yaqoob P. Effect of a synbiotic on the response to seasonal influenza vaccination is strongly influenced by degree of immunosenescence. Immun Ageing. 2016 Mar 15;13:6. doi: 10.1186/s12979-016-0061-4. eCollection 2016. — View Citation
Taves DR. Minimization: a new method of assigning patients to treatment and control groups. Clin Pharmacol Ther. 1974 May;15(5):443-53. doi: 10.1002/cpt1974155443. No abstract available. — View Citation
Vega-Villa KR, Remsberg CM, Ohgami Y, Yanez JA, Takemoto JK, Andrews PK, Davies NM. Stereospecific high-performance liquid chromatography of taxifolin, applications in pharmacokinetics, and determination in tu fu ling (Rhizoma smilacis glabrae) and apple (Malus x domestica). Biomed Chromatogr. 2009 Jun;23(6):638-46. doi: 10.1002/bmc.1165. — View Citation
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phagocytosis activity by granulocytes ex vivo | Mean fluorescence intensity per cell will be assessed by flow cytometry. | 8 weeks post intervention | |
Secondary | Percentage phagocytosis by monocytes ex vivo | Percentage of cells undergoing phagocytosis will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Phagocytosis activity by monocytes ex vivo | Mean fluorescence intensity per cell will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Percentage phagocytosis by granulocytes ex vivo | Percentage of cells undergoing phagocytosis will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Phagocytosis activity by granulocytes ex vivo | Mean fluorescence intensity per cell will be assessed by flow cytometry. | 4 weeks, 3 months post intervention | |
Secondary | Percentage oxidative burst by monocytes ex vivo | Percentage of cells undergoing oxidative burst will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Oxidative burst activity by monocytes ex vivo | Mean fluorescence intensity per cell will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Percentage oxidative burst by granulocytes ex vivo | Percentage of cells undergoing oxidative burst will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Oxidative burst activity by granulocytes ex vivo | Mean fluorescence intensity per cell will be assessed by flow cytometry. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Frequencies of naive T cells | The proportion of naive T cells will be assessed by flow cytometry. | 8 weeks | |
Secondary | Frequencies of memory T cells | The proportion of memory T cells will be assessed by flow cytometry. | 8 weeks | |
Secondary | CD57 expression upon T cells. | The proportion of T cells expressing CD57 (a marker associated with chronic immune activation) and the mean fluorescence intensity per cell will be assessed by flow cytometry. | 8 weeks | |
Secondary | CD28 expression upon T cells. | The proportion of T cells expressing CD28 (a cell surface marker required for T cell activation and survival) and the mean fluorescence intensity per cell will be assessed by flow cytometry. | 8 weeks | |
Secondary | Plasma lipid peroxides | Participant plasma lipid peroxides will be measured by colorimetric analysis. | 8 weeks | |
Secondary | Urinary isoprostanes | Participant urinary isoprostanes will be measured by commercially available ELISA. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Plasma isoprostanes | Participant plasma isoprostanes will be measured by commercially available ELISA. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Cytokine production by cryopreserved peripheral blood mononuclear cells in response to lipopolyssaccharide | A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array. | 4 weeks, 8 weeks | |
Secondary | Cytokine production by cryopreserved peripheral blood mononuclear cells in response to influenza or coronavirus vaccine products | A panel of pro- and anti-inflammatory cytokines secreted by immune cells ex vivo will be assessed by Luminex array. | 4 weeks, 8 weeks | |
Secondary | Metabolomic analysis of urine samples | Full metabolic profiling of first-morning urine samples will be used to assess changes to metabolic activity of participants and their microbiome. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Metabolomic analysis of serum samples | Full metabolic profiling of serum samples will be used to assess changes to metabolic activity of participants. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Faecal microbiome analysis | Sequences of ribosomal RNA (rRNA) in participant faecal samples will be measured to assess changes in the numbers or proportions of bacterial genera and species/strains. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Incidence of self-reported seasonal cold, coronavirus and influenza-like illness. | A daily online form will be completed by participants to log any seasonal cold, coronavirus and influenza-like illness. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Duration of self-reported illness. | A daily online form will be completed by participants to log any self-reported illness. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Severity of self-reported illness. | A daily online form will be completed by participants to log any self-reported illness. | 4 weeks, 8 weeks, 3 months post intervention | |
Secondary | Self-reported medication use. | A daily online form will be completed by participants to log any medication use. | 4 weeks, 8 weeks, 3 months post intervention |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05523089 -
The Effectiveness of CD388 to Prevent Flu in an Influenza Challenge Model in Healthy Adults
|
Phase 2 | |
Completed |
NCT05009251 -
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
|
N/A | |
Completed |
NCT03282240 -
Safety and Immunogenicity of High-Dose Quadrivalent Influenza Vaccine in Participants ≥65 Years in the US
|
Phase 3 | |
Completed |
NCT00968526 -
Study to Evaluate Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00968539 -
Study to Evaluate the Immunogenicity & Safety of an Investigational Influenza Vaccine (H1N1) in Adults
|
Phase 3 | |
Completed |
NCT00971425 -
Evaluation of the Immune Response and the Safety of a Pandemic Influenza Candidate Vaccine (H1N1)
|
Phase 3 | |
Completed |
NCT05525494 -
Patient Portal Flu Vaccine Reminders (5)
|
N/A | |
Completed |
NCT04074928 -
Safety and Immunogenicity Study of QIVc in Healthy Pediatric Subjects
|
Phase 3 | |
Completed |
NCT04695717 -
This Study Was Conducted to Evaluate the Safety and Immunogenicity of IVACFLU-S Produced in Children From 6 Months to Under 18 Years Old and the Elderly Over 60 Years Old in Vietnam
|
Phase 3 | |
Completed |
NCT05012163 -
Lottery Incentive Nudges to Increase Influenza Vaccinations
|
N/A | |
Completed |
NCT03888989 -
Response to Influenza Vaccine During Pregnancy
|
Phase 1 | |
Completed |
NCT04109222 -
Collection of Serum Samples From Children and Older Adults Receiving the 2019-2020 Formulations of Fluzone® Quadrivalent and Fluzone® High-Dose Influenza Vaccines, Respectively
|
Phase 4 | |
Completed |
NCT02587221 -
Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of an MF59-Adjuvanted Quadrivalent Influenza Vaccine Compared to Non-influenza Vaccine Comparator in Adults ≥ 65 Years of Age
|
Phase 3 | |
Completed |
NCT03453801 -
The Role of CD4+ Memory Phenotype, Memory, and Effector T Cells in Vaccination and Infection
|
Phase 1 | |
Completed |
NCT01440387 -
A Study of Immunogenicity and Safety of GSK Biologicals' Influenza Vaccine FLU-Q-QIV in Adults Aged 18 Years and Older
|
Phase 3 | |
Terminated |
NCT01195779 -
Trial to Evaluate Safety and Immunogenicity of GSK Biologicals' Influenza Vaccine GSK2584786A in Healthy Children
|
Phase 2 | |
Completed |
NCT03321968 -
Lot-to-lot Consistency of a Plant-Derived Quadrivalent Virus-Like Particles Influenza Vaccine in Healthy Adults
|
Phase 3 | |
Completed |
NCT00972517 -
Study to Evaluate the Immunogenicity and Safety of an Investigational Influenza Vaccine (H1N1) in Children
|
Phase 3 | |
Completed |
NCT04570904 -
Broadening Our Understanding of Early Versus Late Influenza Vaccine Effectiveness
|
||
Recruiting |
NCT03331991 -
Prevention of Influenza and Other Wintertime Respiratory Viruses Among Healthcare Professionals in Israel
|
N/A |